ESR1 and breast cancer: Mast cells are more abundant in the TME of luminal breast cancers, as compared to basal-like tumors50 and have been correlated to residual disease after neo-adjuvant chemotherapy51 and a non-pCR in the pembrolizumab and durvalumab/olaparib arm in the ER-positive subgroup of the I-SPY2 trial32,42.